Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
NO INCREASE OF SERUM AUTOANTIBODIES DURING THERAPY WITH RECOMBINANT HUMAN INTERFERON-BETA(1A) IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS
Autore:
COLOSIMO C; POZZILLI C; FRONTONI M; FARINA D; KOUDRIAVTSEVA T; GASPERINI C; SALVETTI M; VALESINI G;
Indirizzi:
UNIV ROMA LA SAPIENZA,DIPARTIMENTO SCI NEUROL,NEUROL CLIN 1A I-00185 ROME ITALY UNIV ROMA LA SAPIENZA,ALLERGOL & IMMUNOL CLIN 3,NEUROL CLIN 1A I-00185 ROME ITALY
Titolo Testata:
Acta neurologica Scandinavica
fascicolo: 6, volume: 96, anno: 1997,
pagine: 372 - 374
SICI:
0001-6314(1997)96:6<372:NIOSAD>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTIBODIES; DISEASE;
Keywords:
ANA; ANTICARDIOLIPIN; ANTITHYROID; INTERFERON BETA; MULTIPLE SCLEROSIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
13
Recensione:
Indirizzi per estratti:
Citazione:
C. Colosimo et al., "NO INCREASE OF SERUM AUTOANTIBODIES DURING THERAPY WITH RECOMBINANT HUMAN INTERFERON-BETA(1A) IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS", Acta neurologica Scandinavica, 96(6), 1997, pp. 372-374

Abstract

Objectives - The present investigation was aimed at establishing whether interferon (IFN)-beta would induce the synthesis of autoantibodiesin patients affected by multiple sclerosis (MS). Materials and methods - The titres of different autoantibodies were measured in a group of68 relapsing-remitting MS patients before and during treatment with human recombinant IFN-beta(1a) (3 MIU or 9 MIU subcutaneously 3 x a week). ANA, anti-thyroid, anticardiolipin serum autoantibodies were assayed in all cases: when patients were found positive to ANA>:40, they were also tested for anti-DNA and anti-ENA antibodies. Results - No increase was found in autoantibodies synthesis during 6 months of r-hIFN beta(1a) therapy, either at low or high dosages. The percentage of patients positive to different types of autoantibodies varied between 0 and 29%, which are values similar to those already reported in untreatedMS patients, Conclusion - Our data indicate tl;at the short-term use of IFN-beta(1a) in MS is safe in terms of the induction of humoral autoimmune responses: however. Further follow-up is needed to confirm these findings during long-term treatments.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 10:36:44